CClinicalTrials.gg
CompletedNCT05442606Updated Oct 26, 2023

Physiotherapy Protocol in Treating Chronic Rhinosinusitis

An interventional study of Ultrasound Therapy and Manual Drainage Techniques in Rhinosinusitis, sponsored by Cairo University. Completed at 1 site in Saudi Arabia. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
All
01

Study summary

This study aims to investigate the effect of adding of integrated physiotherapy program to the conservative medical therapy on quality of life and pressure pain threshold (PPT) in chronic rhinosinusitis patients. Patients in this study will be randomly assigned into 2 groups. Group A (control group) will receive conservative medical treatment only which prescribed by Ear, Nose and Throat (ENT) specialist, while group B (experimental group) will receive the conservative medical treatment prescribed by ENT specialist in addition to physiotherapy program. Quality of Life (QoL) will be evaluated by Rhinosinusitis Disability Index (RSDI) and PPT will be evaluated by digital algometer at the baseline and immediately after the end of tenth session of treatment for both groups.

Read the detailed description

Sixty-eight patients will be recruited for this study from Al-Qurayyat General Hospital in Al-Jouf Region, Saudi Arabia, with the following inclusion criteria: patients of both sexes, aged from 30 to 50 years, diagnosed by ENT specialist, with chronic rhinosinusitis with a history of 3 months or longer. The patients will be allocated into two equal groups at random (n = 34). Group A (control group) will receive medication only which prescribed by ENT specialist. Group B (experimental group) will receive prescribed medication by ENT specialist in addition to physiotherapy program which consists of: Ultrasound Therapy: The patients will receive pulsed (duty cycle 50%) US therapy with an intensity of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, with a frequency of 1MHz collimating beam. The small probe US applicator (0.8 cm2) with effective radiating area (ERA) equal 0.6 cm2 and beam non-uniformity ratio (BNR) equal 6:1 will be used to deliver US to the treatment area. The area of US application will be the skin over the cheeks for maxillary sinus and forehead for the frontal sinus. Ultrasound transmission gel will be used between the applicator and the skin, full contact technique in slow circular motion will be used for the duration of 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses. Manual Drainage Techniques: for the frontal and maxillary sinuses. Self Massaging Technique: The patients will also advised to perform self-massaging for the frontal and maxillary sinuses from the supine lying position. A demonstration session will be used to provide patients in the experimental group with a full description of the manual therapy procedure before the beginning of the study. The physiotherapy program will be applied 3 times a week (day after day) for 12 treatment sessions.

02

Conditions studied

  • Rhinosinusitis

Keywords

  • Rhinosinusitis
  • ultrasound therapy
  • quality of life
  • pain threshold
  • manual therapy
03

In context

Rhinosinusitis

330 studies on the registry are indexed under Rhinosinusitis; 55 are open to participants now.

This study's enrollment of 68 is above the median of 60 across 227 interventional studies indexed under Rhinosinusitis.

Browse Rhinosinusitis studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients of both sexes
  • Aged from 30 to 50 years
  • Cynically diagnosed by Ear, Nose, and Throat (ENT) specialist, with chronic rhinosinusitis with a history of more than 3 months, confirmed by clinical diagnostic criteria (more than or equal to two major symptoms or one major symptom (nasal obstruction, facial pain/pressure, postnasal drip and hyposmia) and two minor symptoms (headache, halitosis, fatigue, dental pain and ear pain) and also verified by Computed Tomography (CT) scan results .

Exclusion criteria

Exclusion criteria:

  • Having any tumors or cysts (as confirmed by CT scan)
  • Nasal polyps
  • Facial skin lesions or diseases or allergies of the face
  • Pregnancy
  • Metal implants in the face region
  • Previous nasal surgical procedures
  • Impaired thermal sensation (such as uncontrolled diabetes mellitus)
  • Cognitive level impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • No intervention
    Conservative medical therapy

    Patients in this group received only medication prescribed by an Ear, Nose and Throat specialist.

  • Experimental
    Medication and Physiotherapy program

    Patients in this group received medication prescribed by an Ear, Nose and Throat specialist, in addition to integrated Physiotherapy program

    Other: Ultrasound Therapy · Other: Manual Drainage Techniques · Other: Self Sinus Massage Technique

Interventions

  • OtherUltrasound Therapy

    Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses

  • OtherManual Drainage Techniques

    Manual Drainage Techniques for the frontal and maxillary sinuses

  • OtherSelf Sinus Massage Technique

    Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine

06

What researchers measure

Primary outcomes

  1. Rhinosinusitis Disability Index (RSDI)

    Arabic version of Rhinosinusitis Disability Index will be used to assess the change in quality of life

    Time frame: From baseline to 4 weeks after treatment (immediately after the completion of session 12)

Secondary outcomes

  1. Pressure pain threshold

    Wagner FPX25 digital algometer will be used to assess the change in pressure pain threshold

    Time frame: From baseline to 4 weeks after treatment (immediately after the completion of session 12)

07

Study locations

1 site
  • Al Qurayyat General Hospital
    Al Qurayyat, Jouf Region 77471, Saudi Arabia
08

References and documents

Related links

Individual participant data

Plan to share: Yes — The IPD will be shared including a summary of the results after the study completion date.

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05442606
Lead sponsor
Cairo University
Collaborators
Jouf University
Responsible party
Khaled Z. Fouda (Associate Professor of Physical therapy, Cairo University) — Principal investigator
First posted
Jul 5, 2022
Start date
Sep 1, 2022
Primary completion
Mar 1, 2023
Completion
Mar 21, 2023
Last update
Oct 26, 2023

Study contacts

Khaled Fouda, PhD
principal investigator · Associate Professor of Physical Therapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion